#BEGIN_DRUGCARD DB04173

# AHFS_Codes:
Not Available

# ATC_Codes:
V06DC02

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
28757

# Chemical_Formula:
C6H12O6

# Chemical_IUPAC_Name:
(2S,3R,4R,5S)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Fructose

# HET_ID:
FRU

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m0/s1

# InChI_Key:
InChIKey=RFSUNEUAIZKAJO-AZGQCCRYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4173

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
180.1559

# Molecular_Weight_Mono:
180.063388116

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1Y9G

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449716

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.5

# Predicted_LogS:
0.79

# Predicted_Water_Solubility:
1.11e+03 g/l

# Primary_Accession_No:
DB04173

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
439553

# PubChem_Substance_ID:
46504785

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01495

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:02 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell outer membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M26131

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
lamB

# Drug_Target_1_Gene_Sequence:
>1341 bp
ATGATGATTACTCTGCGCAAACTTCCTCTGGCGGTTGCCGTCGCAGCGGGCGTAATGTCT
GCTCAGGCAATGGCTGTTGATTTCCACGGCTATGCACGTTCCGGTATTGGTTGGACAGGT
AGCGGCGGTGAACAACAGTGTTTCCAGACTACCGGTGCTCAAAGTAAATACCGTCTTGGC
AACGAATGTGAAACTTATGCTGAATTAAAATTGGGTCAGGAAGTGTGGAAAGAGGGCGAT
AAGAGCTTCTATTTCGACACTAACGTGGCCTATTCCGTCGCACAACAGAATGACTGGGAA
GCTACCGATCCGGCCTTCCGTGAAGCAAACGTGCAGGGTAAAAACCTGATCGAATGGCTG
CCAGGCTCCACCATCTGGGCAGGTAAGCGCTTCTACCAACGTCATGACGTTCATATGATC
GACTTCTACTACTGGGATATTTCTGGTCCTGGTGCCGGTCTGGAAAACATCGATGTTGGC
TTCGGTAAACTCTCTCTGGCAGCAACCCGCTCCTCTGAAGCTGGTGGTTCTTCCTCTTTC
GCCAGCAACAATATTTATGACTATACCAACGAAACCGCGAACGACGTTTTCGATGTGCGT
TTAGCGCAGATGGAAATCAACCCGGGCGGCACATTAGAACTGGGTGTCGACTACGGTCGT
GCCAACTTGCGTGATAACTATCGTCTGGTTGATGGCGCATCGAAAGACGGCTGGTTATTC
ACTGCTGAACATACTCAGAGTGTCCTGAAGGGCTTTAACAAGTTTGTTGTTCAGTACGCT
ACTGACTCGATGACCTCGCAGGGTAAAGGGCTGTCGCAGGGTTCTGGCGTTGCATTTGAT
AACGAAAAATTTGCCTACAATATCAACAACAACGGTCACATGCTGCGTATCCTCGACCAC
GGTGCGATCTCCATGGGCGACAACTGGGACATGATGTACGTGGGTATGTACCAGGATATC
AACTGGGATAACGACAACGGCACCAAGTGGTGGACCGTCGGTATTCGCCCGATGTACAAG
TGGACGCCAATCATGAGCACCGTGATGGAAATCGGCTACGACAACGTCGAATCCCAGCGC
ACCGGCGACAAGAACAATCAGTACAAAATTACCCTCGCACAACAATGGCAGGCTGGCGAC
AGCATCTGGTCACGCCCGGCTATTCGTGTCTTCGCAACCTACGCCAAGTGGGATGAGAAA
TGGGGTTACGACTACACCGGTAACGCTGATAACAACGCGAACTTCGGCAAAGCCGTTCCT
GCTGATTTCAACGGCGGCAGCTTCGGTCGTGGCGACAGCGACGAGTGGACCTTCGGTGCC
CAGATGGAAATCTGGTGGTAA

# Drug_Target_1_General_Function:
Involved in sugar:hydrogen ion symporter activity

# Drug_Target_1_General_References:
161974	Clement JM, Hedgpeth J, Hofnung M: [DNA sequence encoding the signal peptide of the lambda receptor in E. coli K 12] C R Seances Acad Sci D. 1979 Nov 26;289(14):1033-6.
1702781	Charbit A, Ronco J, Michel V, Werts C, Hofnung M: Permissive sites and topology of an outer membrane protein with a reporter epitope. J Bacteriol. 1991 Jan;173(1):262-75.
1988451	Luckey M, Ling R, Dose A, Malloy B: Role of a disulfide bond in the thermal stability of the LamB protein trimer in Escherichia coli outer membrane. J Biol Chem. 1991 Jan 25;266(3):1866-71.
2832377	Heine HG, Francis G, Lee KS, Ferenci T: Genetic analysis of sequences in maltoporin that contribute to binding domains and pore structure. J Bacteriol. 1988 Apr;170(4):1730-8.
3301537	Heine HG, Kyngdon J, Ferenci T: Sequence determinants in the lamB gene of Escherichia coli influencing the binding and pore selectivity of maltoporin. Gene. 1987;53(2-3):287-92.
6086106	Clement JM, Hofnung M: Gene sequence of the lambda receptor, an outer membrane protein of E. coli K12. Cell. 1981 Dec;27(3 Pt 2):507-14.
6446717	Hedgpeth J, Clement JM, Marchal C, Perrin D, Hofnung M: DNA sequence encoding the NH2-terminal peptide involved in transport of lambda receptor, an Escherichia coli secretory protein. Proc Natl Acad Sci U S A. 1980 May;77(5):2621-5.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5498

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
49913

# Drug_Target_1_Name:
Maltoporin

# Drug_Target_1_Number_of_Residues:
446

# Drug_Target_1_PDB_ID:
1MPQ

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02264	LamB

# Drug_Target_1_Protein_Sequence:
>Maltoporin
MMITLRKLPLAVAVAAGVMSAQAMAVDFHGYARSGIGWTGSGGEQQCFQTTGAQSKYRLG
NECETYAELKLGQEVWKEGDKSFYFDTNVAYSVAQQNDWEATDPAFREANVQGKNLIEWL
PGSTIWAGKRFYQRHDVHMIDFYYWDISGPGAGLENIDVGFGKLSLAATRSSEAGGSSSF
ASNNIYDYTNETANDVFDVRLAQMEINPGGTLELGVDYGRANLRDNYRLVDGASKDGWLF
TAEHTQSVLKGFNKFVVQYATDSMTSQGKGLSQGSGVAFDNEKFAYNINNNGHMLRILDH
GAISMGDNWDMMYVGMYQDINWDNDNGTKWWTVGIRPMYKWTPIMSTVMEIGYDNVESQR
TGDKNNQYKITLAQQWQAGDSIWSRPAIRVFATYAKWDEKWGYDYTGNADNNANFGKAVP
ADFNGGSFGRGDSDEWTFGAQMEIWW

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-25

# Drug_Target_1_Specific_Function:
Involved in the transport of maltose and maltodextrins, indispensable for translocation of dextrins containing more than three glucosyl moieties. A hydrophobic path ("greasy slide") of aromatic residues serves to guide and select the sugars for transport through the channel. Also acts as a receptor for several bacteriophages including lambda

# Drug_Target_1_SwissProt_ID:
P02943

# Drug_Target_1_SwissProt_Name:
LAMB_ECOLI

# Drug_Target_1_Synonyms:
Lambda receptor protein
Maltoporin precursor
Maltose-inducible porin

# Drug_Target_1_Theoretical_pI:
4.58

# Drug_Target_1_Transmembrane_Regions:
27-35
65-78
81-93
105-115
123-130
149-159
162-173
192-205
210-222
235-248
251-263
291-305
308-323
327-341
344-359
363-378
386-400
431-445

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
FHIT

# Drug_Target_2_GenBank_ID_Gene:
U46922

# Drug_Target_2_GenBank_ID_Protein:
1203836

# Drug_Target_2_GeneCard_ID:
FHIT

# Drug_Target_2_Gene_Name:
FHIT

# Drug_Target_2_Gene_Sequence:
>444 bp
ATGTCGTTCAGATTTGGCCAACATCTCATCAAGCCCTCTGTAGTGTTTCTCAAAACAGAA
CTGTCCTTCGCTCTTGTGAATAGGAAACCTGTGGTACCAGGACATGTCCTTGTGTGCCCG
CTGCGGCCAGTGGAGCGCTTCCATGACCTGCGTCCTGATGAAGTGGCCGATTTGTTTCAG
ACGACCCAGAGAGTCGGGACAGTGGTGGAAAAACATTTCCATGGGACCTCTCTCACCTTT
TCCATGCAGGATGGCCCCGAAGCCGGACAGACTGTGAAGCACGTTCACGTCCATGTTCTT
CCCAGGAAGGCTGGAGACTTTCACAGGAATGACAGCATCTATGAGGAGCTCCAGAAACAT
GACAAGGAGGACTTTCCTGCCTCTTGGAGATCAGAGGAGGAAATGGCAGCAGAAGCCGCA
GCTCTGCGGGTCTACTTTCAGTGA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
8598045	Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996 Feb 23;84(4):587-97.
8794732	Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K: Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. Biochemistry. 1996 Sep 10;35(36):11529-35.
9012482	Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 1997 Feb 1;57(3):504-12.
9261067	Lima CD, D'Amico KL, Naday I, Rosenbaum G, Westbrook EM, Hendrickson WA: MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family. Structure. 1997 Jun 15;5(6):763-74.
9323207	Lima CD, Klein MG, Hendrickson WA: Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science. 1997 Oct 10;278(5336):286-90.
9576908	Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosler A, Blackburn GM, Siprashvili Z, Croce CM, Huebner K, Brenner C: Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci U S A. 1998 May 12;95(10):5484-9.

# Drug_Target_2_HGNC_ID:
HGNC:3701

# Drug_Target_2_HPRD_ID:
03096

# Drug_Target_2_ID:
3075

# Drug_Target_2_Locus:
3p14.2

# Drug_Target_2_Molecular_Weight:
16858

# Drug_Target_2_Name:
Bis(5'-adenosyl)-triphosphatase

# Drug_Target_2_Number_of_Residues:
147

# Drug_Target_2_PDB_ID:
1FHI

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01230	HIT

# Drug_Target_2_Protein_Sequence:
>Bis(5'-adenosyl)-triphosphatase
MSFRFGQHLIKPSVVFLKTELSFALVNRKPVVPGHVLVCPLRPVERFHDLRPDEVADLFQ
TTQRVGTVVEKHFHGTSLTFSMQDGPEAGQTVKHVHVHVLPRKAGDFHRNDSIYEELQKH
DKEDFPASWRSEEEMAAEAAALRVYFQ

# Drug_Target_2_Reaction:
P1,P3-bis(5'-adenosyl) triphosphate + H2O = ADP + AMP

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Cleaves A-5'-PPP-5'A to yield AMP and ADP. Possible tumor suppressor for specific tissues

# Drug_Target_2_SwissProt_ID:
P49789

# Drug_Target_2_SwissProt_Name:
FHIT_HUMAN

# Drug_Target_2_Synonyms:
AP3A hydrolase
AP3AASE
Diadenosine 5',5'''- P1,P3-triphosphate hydrolase
Dinucleosidetriphosphatase
EC 3.6.1.29
Fragile histidine triad protein

# Drug_Target_2_Theoretical_pI:
7.09

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04173
